Drug-induced lupus and antiphospholipid syndrome associated with cysteamine therapy

Nephrology Dialysis Transplantation

Volumn 24, Issue 6, 2009, Pages 1997-1999

  Krischock, Leah ^a   Horsfield, Catherine ^a   D'Cruz, David ^a   Rigden, Susan P A ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Antiphospholipid syndrome; Cysteamine; Drug induced lupus; Nephropathic cystinosis

Indexed keywords

ANTINUCLEAR ANTIBODY; CARDIOLIPIN ANTIBODY; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4 BINDING PROTEIN; DOUBLE STRANDED DNA ANTIBODY; ENALAPRIL; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LUPUS ANTICOAGULANT; MERCAPTAMINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RAPAMYCIN; TACROLIMUS;

ABDOMINAL PAIN; ADD ON THERAPY; ADOLESCENT; ANEMIA; ANTIBODY BLOOD LEVEL; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CASE REPORT; CHILD; COMPLEMENT BLOOD LEVEL; CYSTINOSIS; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GASTROINTESTINAL ENDOSCOPY; HISTOPATHOLOGY; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; LUPUS LIKE SYNDROME; NEPHRECTOMY; NEPHROPATHIC CYSTINOSIS; OUTCOME ASSESSMENT; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PRIORITY JOURNAL; PROTEINURIA;

ADOLESCENT; ANTIBODIES, ANTINUCLEAR; ANTIPHOSPHOLIPID SYNDROME; BLOOD SEDIMENTATION; CYSTEAMINE; CYSTINOSIS; FEMALE; HUMANS; KIDNEY TRANSPLANTATION; LUPUS NEPHRITIS;

EID: 67651087327     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfp128     Document Type: Article

References (8)

1. Borchers AT, Keen CL, Gershwin ME. Drug-induced lupus. Ann N Y Acad Sci 2007; 1108: 166-182
2. Rubin RL. Etiology and mechanisms of drug-induced lupus. Curr Opin Rheumatol 1999; 11: 357-363
3. Miyakis S, Lockshin MD, Atsumi T et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295-306
4. Nesterova G, Gahl W. Nephropathic cystinosis: late complications of a multisystemic disease. Pediatr Nephrol 2007;
5. Suwannaroj S, Lagoo A, Keisler D et al. Antioxidants suppress mortality in the female NZB × NZW F1 mouse model of systemic lupus erythematosus (SLE). Lupus 2001; 10: 258-265
6. Benke PJ, Levcovitz H, Paupe J et al. Scavengers of free radical oxygen affect the generation of low molecular weight DNA in stimulated lym-phocytes from patients with systemic lupus erythematosus. Metabolism 1990; 39: 1278-1284
7. Lockshin M, Derksen R. New developments in lupus-associated antiphospholipid syndrome. Lupus 2008; 17: 443-446
8. Drouvalakis KA, Buchanan RR. Phospholipid specificity of autoimmune and drug induced lupus anticoagulants: association of phosphatidylethanolamine reactivity with thrombosis in autoimmune disease. J Rheumatol 1998; 25: 290-295